Currently, there are 100.11M common shares owned by the public and among those 91.68M shares have been available to trade.
Insiders at the company have transacted a total of 61 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 37 of these insider trades were purchases, accounting for 1,349,835 shares. Insider sales of the common stock occurred on 24 occasions, with total insider shares sold totaling 1,490,123 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 94.67, up 7.18%. The company’s stock has a 5-day price change of 137.37% and 647.46% over the past three months. VKTX shares are trading 390.81% year to date (YTD), with the 12-month market performance up to 696.34% higher. It has a 12-month low price of $8.28 and touched a high of $99.41 over the same period. VKTX has an average intraday trading volume of 5.32 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 116.55%, 212.10%, and 389.73% respectively.
Institutional ownership of Viking Therapeutics Inc (NASDAQ: VKTX) shares accounts for 75.10% of the company’s 100.11M shares outstanding.
It has a market capitalization of $9.18B and a beta (3y monthly) value of 1.05. The earnings-per-share (ttm) stands at -$0.91. Price movements for the stock have been influenced by the stock’s volatility, which stands at 22.83% over the week and 12.13% over the month.
Analysts forecast that Viking Therapeutics Inc (VKTX) will achieve an EPS of -$0.28 for the current quarter, -$0.28 for the next quarter and -$1.47 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.32 while analysts give the company a high EPS estimate of -$0.24. Comparatively, EPS for the current quarter was -$0.25 a year ago. Earnings per share for the fiscal year are expected to decrease by -22.99%, and -31.72% over the next financial year. EPS should grow at an annualized rate of 40.00% over the next five years, compared to -18.89% over the past 5-year period.
Looking at the support for the VKTX, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on February 28, 2024, with the firm’s price target at $46-$116. ROTH MKM coverage for the Viking Therapeutics Inc (VKTX) stock in a research note released on May 31, 2023 offered a Buy rating with a price target of $32. Maxim Group was of a view on March 28, 2023 that the stock is Buy, while Stifel gave the stock Buy rating on March 17, 2023, issuing a price target of $22. BTIG Research on their part issued Buy rating on July 29, 2021.
